Our results demonstrated that HER2 ultra-low BC patients had distinct clinicopathological features from HER2-null and HER2-low tumors; while, HER2 status (null, ultra-low, or low) had no prognostic value in these HER2-negative BC population. The gene discussed is ERBB2; the disease is breast cancer.